A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

NCT07737743 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Sjögren's Disease

Interventions

DRUG: DDY391
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals